CompagOS has produced biologically reproducible Bon3OID™ bone models using 3D bioprinting. Find out more in the interview!

A new biopharmaceutical company is devoted to developing therapies for rare bone diseases in Montreal. Ocythera was launched ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

Explore the vital role of bone marrow stem cells. Learn how they drive bone remodeling, immunity, and skeletal health in this complete guide.

Know how poor sleep and vitamin D deficiency in children can impact brain growth, immunity, focus, behavior, and long-term ...

The global HLA typing market is expected to expand at a compound annual growth rate (CAGR) of approximately 6% during the ...

Majestic, powerful, and remarkably calm: The Drum Horse immediately draws all eyes. Once it carried kettledrums through the ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

This is the third program that successfully combines Entera's oral peptide N-Tab- platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to ...

The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. -- There has been no safety concern with the use ...

Medanta–The Medicity, in collaboration with the Investment & Development Authority of Nagaland (IDAN) and the Government of ...

The global nutraceuticals market, valued at approximately USD 416 billion in 2026, is projected to grow at a CAGR of around 9% over the next five years.Key factors driving this growth include ...